| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/12/2011 | US20110110908 Treatment of disease conditions via administration of dna repair enzyme |
| 05/12/2011 | US20110110899 Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells |
| 05/12/2011 | US20110110891 Methods of Treating Hepatitis C Virus Infection |
| 05/12/2011 | US20110110890 Novel Inhibitors of Hepatitis C Virus Replication |
| 05/12/2011 | US20110110889 Raf inhibitor compounds and methods of use thereof |
| 05/12/2011 | US20110110888 Scaffold Coated and/or Impregnated with at Least One Bioactive Agent for Tissue Repair and Other Medical Applications |
| 05/12/2011 | US20110110886 Small molecule inhibitors of autotaxin and methods of use |
| 05/12/2011 | US20110110885 Bioactive Depside and Anthocyanin Compounds, Compositions, and Methods of Use |
| 05/12/2011 | US20110110884 Immunotherapy for immune suppressed patients |
| 05/12/2011 | US20110110883 Methods of altering an immune response induced by cpg oligodeoxynucleotides |
| 05/12/2011 | US20110110882 Cross-linked compositions |
| 05/12/2011 | US20110110875 Angiogenic peptide |
| 05/12/2011 | US20110110855 Novel ghrelin analogues |
| 05/12/2011 | US20110110854 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules |
| 05/12/2011 | US20110110851 Multivalent Immunoglobulin-Based Bioactive Assemblies |
| 05/12/2011 | CA2780362A1 Administration of plant expressed oral tolerance agents |
| 05/12/2011 | CA2780337A1 Linaclotide for the treatment of chronic constipation |
| 05/12/2011 | CA2780193A1 Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract |
| 05/12/2011 | CA2780163A1 Method for treating heart failure with stresscopin-like peptides |
| 05/12/2011 | CA2779515A1 Haemophilus parasuis polypeptides and methods of use |
| 05/12/2011 | CA2779472A1 Methods for treating fatty liver disease |
| 05/12/2011 | CA2779433A1 Composition for promoting wound healing |
| 05/12/2011 | CA2779369A1 Composition, method, and kit for alpha-1 proteinase inhibitor |
| 05/12/2011 | CA2778806A1 Methods and kits for preventing hypoglycemia |
| 05/12/2011 | CA2778234A1 Methods and compositions for modulating tau levels |
| 05/12/2011 | CA2777552A1 Cardiomyocyte production |
| 05/11/2011 | EP2319935A2 GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants |
| 05/11/2011 | EP2319934A2 GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants |
| 05/11/2011 | EP2319931A1 Extracellular matrix-binding proteins from staphylococcus aureus |
| 05/11/2011 | EP2319928A1 Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
| 05/11/2011 | EP2319917A2 Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| 05/11/2011 | EP2319871A1 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| 05/11/2011 | EP2319866A2 Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications |
| 05/11/2011 | EP2319859A2 Spatially-defined macrocyclic compounds useful for drug discovery |
| 05/11/2011 | EP2319547A2 Matrix for the production of ligaments, tendons and other tissue |
| 05/11/2011 | EP2319541A1 Factor VII or VIIA-like conjugates |
| 05/11/2011 | EP2319537A1 Stabilizer for lymph vessel |
| 05/11/2011 | EP2319535A2 Pharmaceutical composition for treatment of diseases caused by IL-6 production |
| 05/11/2011 | EP2319533A1 Immunity-inducing agent and method for detection of cancer |
| 05/11/2011 | EP2319532A1 Recombinant dengue virus containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 3, or 4 |
| 05/11/2011 | EP2319531A2 Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| 05/11/2011 | EP2319530A1 Method for treating and/or preventing multiple sclerosis, and use of erythropoietin in the production of a drug for intermittent treatment and/or intermittent prevention of multiple sclerosis |
| 05/11/2011 | EP2319529A1 Methods for treating congestive heart failure |
| 05/11/2011 | EP2319528A2 Methods of increasing platelet and hematopoietic stem cell production |
| 05/11/2011 | EP2319527A2 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/11/2011 | EP2319526A1 Tdf-related compounds and analogs thereof |
| 05/11/2011 | EP2319525A1 Composition for treating insulin resistance |
| 05/11/2011 | EP2319524A1 Prostate stem cell antigen (PSCA) variants and subsequences thereof |
| 05/11/2011 | EP2319523A1 Serine protease inhibitors |
| 05/11/2011 | EP2319507A1 Therapeutic methods employing nitric oxide precursors |
| 05/11/2011 | EP2319503A2 Drug delivery carrier |
| 05/11/2011 | EP2319500A1 Rapid acting drug delivery compositions |
| 05/11/2011 | EP2319489A2 Oral care composition comprising ovomucin and mannoprotein |
| 05/11/2011 | EP2318534A1 Method for the expression in plant of the glutamic acid decarboxylase (gad65) and related expression vectors the present invention concerns a method of expression in plant of glutamic acid decarboxylase (gad65), particularly a mutated form of human gad65 (gad65mut), and expression vectors thereof. |
| 05/11/2011 | EP2318529A2 Fgfr extracellular domain acidic region muteins |
| 05/11/2011 | EP2318521A1 Use of a mixture of superoxide dismutase and catalase for treating pruritus and alleviating its symptoms |
| 05/11/2011 | EP2318438A1 Anti-p2x7 peptiden und epitopen |
| 05/11/2011 | EP2318435A2 Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
| 05/11/2011 | EP2318432A2 Halogen-stabilized insulin |
| 05/11/2011 | EP2318431A2 Recombinant pokeweed antiviral proteins, compositions and methods related thereto |
| 05/11/2011 | EP2318429A2 Prominin-1 peptide fragments and uses thereof |
| 05/11/2011 | EP2318428A1 Anticancer compounds |
| 05/11/2011 | EP2318419A1 Boronate ester compounds and pharmaceutical compositions thereof |
| 05/11/2011 | EP2318395A2 Inhibitors of iap |
| 05/11/2011 | EP2318038A1 A therapeutic agent for a lower urinary tract disease and an agent for improving a lower urinary tract symptom |
| 05/11/2011 | EP2318037A2 Method of treating glycogen storage disease |
| 05/11/2011 | EP2318036A2 Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis |
| 05/11/2011 | EP2318035A1 Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| 05/11/2011 | EP2318034A2 Wound healing |
| 05/11/2011 | EP2318033A2 Compositions for the treatment of pain and/or inflamation |
| 05/11/2011 | EP2318032A1 Use of hsp70 as a regulator of enzymatic activity |
| 05/11/2011 | EP2318031A2 Enhanced antiviral therapy methods and devices |
| 05/11/2011 | EP2318030A1 Therapeutic proteins from latex |
| 05/11/2011 | EP2318029A2 Modified bovine g-csf polypeptides and their uses |
| 05/11/2011 | EP2318028A2 Antagonists of activin-actriia and uses for increasing red blood cell levels |
| 05/11/2011 | EP2318021A1 Protocols for treating and preventing obesity and complications arising therefrom |
| 05/11/2011 | EP2318012A2 Methods and compositions for treating and preventing autoimmune diseases |
| 05/11/2011 | EP2317999A2 Methods for modulating angiogenesis via dystrophin dp71 |
| 05/11/2011 | EP2317995A1 Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders |
| 05/11/2011 | EP2317986A2 System for the colon delivery of drugs subject to enzyme degradation and/or poorly absorbed in the gastrointestinal tract |
| 05/11/2011 | EP2317979A2 Pharmaceutical compositions of somatotrophic hormones |
| 05/11/2011 | EP2317975A1 Octreotide implant having a release agent |
| 05/11/2011 | EP2121931B1 Purification of fc-tact fusion proteins using the oilbody technology |
| 05/11/2011 | EP2092069B1 Modified soluble fgf receptor fc fusions with improved biological activity |
| 05/11/2011 | EP2050444B1 Fatigue-reducing agent |
| 05/11/2011 | EP2038415B1 Dph2 gene deletion mutant and uses thereof |
| 05/11/2011 | EP1961764B1 Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient |
| 05/11/2011 | EP1678497B1 Methods and compositions for modulating apoptosis |
| 05/11/2011 | EP1163262B1 Phenylalanine derivatives |
| 05/11/2011 | EP0885002B1 Materials and methods for enhancing cellular internalization |
| 05/11/2011 | CN1688695B New dendritic cell co stimulatory molecules |
| 05/11/2011 | CN1599623B Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 05/11/2011 | CN102056939A Restoration of estrogen receptor-alpha activity |
| 05/11/2011 | CN102056630A Stabilizer for lymph vessel |
| 05/11/2011 | CN102056621A A therapeutic agent for a lower urinary tract disease and an agent for improving a lower urinary tract symptom |
| 05/11/2011 | CN102056620A Suture line administration technique using botulinum toxins |
| 05/11/2011 | CN102056619A Methods of generating and using procollagen |
| 05/11/2011 | CN102056618A Compositions and methods for preventing or treating AIDS |
| 05/11/2011 | CN102056617A Inhibition of angiogenesis |
| 05/11/2011 | CN102056616A TPO mimetic peptide for preventing hematological disorder associated with cancer treatment |